Targeting a diverse spectrum of cancers.
Kinase switch control inhibitors for tumor-targeted and immune-targeted cancer therapies.
Deciphera’s proprietary switch control platform has generated a diverse clinical pipeline of kinase inhibitor drug candidates including tumor-targeted therapies and immuno-targeted therapies.
09/21/18 4:00 PM EDT
© Nasdaq. Minimum 15 minutes delayed.
Deciphera Pharmaceuticals Appoints Daniel C. Martin as Chief Commercial Officer Read More »
Deciphera Pharmaceuticals, Inc. to Participate in Citi’s 13th Annual Biotech Conference Read More »
Deciphera Pharmaceuticals, Inc. Announces Second Quarter 2018 Financial Results Read More »